As of November 8, 2026, 8 holders' latest Schedule 13D or 13G filings report owning 5% or more of Contineum Therapeutics, Inc. The largest reported stake is Janus Henderson Group Plc's, at 7.9%. 19 filings are on record since July 25, 2025 (Schedule 13G, February 17, 2026).
Sell to companies like Contineum Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Johnson & Johnson Innovation - JJDC, Inc. · Sole voting: 0 · Shared voting: 1,979,173 · Sole dispositive: 0 · Shared dispositive: 1,979,173 · SCHEDULE 13G/A, 2026-11-06
- · Reporting person: Fmr LLC · Sole voting: 2,610,006 · Shared voting: 0 · Sole dispositive: 2,610,248 · Shared dispositive: 0 · SCHEDULE 13G, 2026-11-05
- · Reporting person: Franklin Templeton, Inc. · Sole voting: 1,704,550 · Shared voting: 0 · Sole dispositive: 1,704,550 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-10-28
- · Reporting person: Squadron Master Fund LP · Sole voting: 0 · Shared voting: 1,700,000 · Sole dispositive: 0 · Shared dispositive: 1,700,000 · SCHEDULE 13G, 2026-10-28
- · Reporting person: Trails Edge Capital Partners, LP · Sole voting: 1,679,443 · Shared voting: 0 · Sole dispositive: 1,679,443 · Shared dispositive: 0 · SCHEDULE 13G, 2026-10-22
Contineum Therapeutics, Inc. has 19 Schedule 13D or 13G filings on record since 2025-07-25. 8 holders' latest filing reports 5% or more of common stock, $0.001 par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Janus Henderson Group Plc | 7.9% | 2,448,979 | SCHEDULE 13G, 2026-02-17 | 2025-12-31 |
| Fmr LLC | 7.9% | 2,610,248 | SCHEDULE 13G, 2026-11-05 | 2026-09-30 |
| Balyasny Asset Management L.P. | 7.14% | 2,335,550 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| BlackRock, Inc. | 6.3% | 2,049,493 | SCHEDULE 13G, 2026-07-27 | 2026-06-30 |
| Johnson & Johnson Innovation - JJDC, Inc. | 5.6% | 1,979,173 | SCHEDULE 13G/A, 2026-11-06 | 2026-11-03 |
| Franklin Templeton, Inc. | 5.2% | 1,704,550 | SCHEDULE 13G/A, 2026-10-28 | 2026-09-30 |
| Trails Edge Capital Partners, LP | 5.1% | 1,679,443 | SCHEDULE 13G, 2026-10-22 | 2026-09-22 |
| Squadron Master Fund LP | 5.1% | 1,700,000 | SCHEDULE 13G, 2026-10-28 | 2026-10-21 |
| RA Capital Management, L.P. | 4% | 1,296,012 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Perceptive Advisors LLC | 3.2% | 699,486 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| Millennium Management LLC | 2.8% | 931,709 | SCHEDULE 13G/A, 2026-07-17 | 2026-06-30 |
Holding shares or following this stake? See who's behind Contineum Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Contineum Therapeutics, Inc. and the records around it.
Contineum Therapeutics, Inc. elsewhere on the record
Companies that share a holder
- Johnson & Johnson Innovation - JJDC, Inc. also filed stake reports on 1 other company: TRex Bio, Inc. (Oct 2026)
- Squadron Master Fund LP also filed stake reports on 14 other companies: TCGX Acquisition Corp. II (Oct 2026), C4 Therapeutics, Inc. (Aug 2026), NextCure, Inc. (Aug 2026)
- Trails Edge Capital Partners, LP also filed stake reports on 16 other companies: Avalo Therapeutics, Inc. (Oct 2026), Sol-Gel Technologies Ltd. (Oct 2026), Faeth Therapeutics, Inc. (Aug 2026)
Watch Contineum Therapeutics, Inc.
Get an email when Contineum Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Contineum Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Contineum Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Contineum Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
19 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Fmr LLC | 2,610,006 | 0 | 2,610,248 | 0 | SCHEDULE 13G, 2026-11-05 |
| Abigail P. Johnson | 0 | 0 | 2,610,248 | 0 | SCHEDULE 13G, 2026-11-05 |
| Balyasny Asset Management L.P. | 2,335,550 | 0 | 2,335,550 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Bam Gp LLC | 2,335,550 | 0 | 2,335,550 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Balyasny Asset Management Holdings LP | 2,335,550 | 0 | 2,335,550 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Dames GP LLC | 2,335,550 | 0 | 2,335,550 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Dmitry Balyasny | 2,335,550 | 0 | 2,335,550 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| BlackRock, Inc. | 2,030,054 | 0 | 2,049,493 | 0 | SCHEDULE 13G, 2026-07-27 |
| Johnson & Johnson Innovation - JJDC, Inc. | 0 | 1,979,173 | 0 | 1,979,173 | SCHEDULE 13G/A, 2026-11-06 |
| Johnson & Johnson | 0 | 1,979,173 | 0 | 1,979,173 | SCHEDULE 13G/A, 2026-11-06 |
| Franklin Templeton, Inc. | 1,704,550 | 0 | 1,704,550 | 0 | SCHEDULE 13G/A, 2026-10-28 |
| Charles B. Johnson | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-10-28 |
| Rupert H. Johnson, Jr. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-10-28 |
| Franklin Advisers, Inc. | 1,704,550 | 0 | 1,704,550 | 0 | SCHEDULE 13G/A, 2026-10-28 |
| Trails Edge Capital Partners, LP | 1,679,443 | 0 | 1,679,443 | 0 | SCHEDULE 13G, 2026-10-22 |
| Trails Edge Biotechnology Master Fund, LP | 1,679,443 | 0 | 1,679,443 | 0 | SCHEDULE 13G, 2026-10-22 |
| Ortav Yehudai | 1,679,443 | 0 | 1,679,443 | 0 | SCHEDULE 13G, 2026-10-22 |
| Squadron Master Fund LP | 0 | 1,700,000 | 0 | 1,700,000 | SCHEDULE 13G, 2026-10-28 |
| Squadron Capital Management LLC | 0 | 1,700,000 | 0 | 1,700,000 | SCHEDULE 13G, 2026-10-28 |
| Matthew Sesterhenn | 0 | 1,700,000 | 0 | 1,700,000 | SCHEDULE 13G, 2026-10-28 |
| William Blank | 0 | 1,700,000 | 0 | 1,700,000 | SCHEDULE 13G, 2026-10-28 |
| Millennium Management LLC | 0 | 931,709 | 0 | 931,709 | SCHEDULE 13G/A, 2026-07-17 |
| Millennium Group Management LLC | 0 | 931,709 | 0 | 931,709 | SCHEDULE 13G/A, 2026-07-17 |
| Israel A. Englander | 0 | 931,709 | 0 | 931,709 | SCHEDULE 13G/A, 2026-07-17 |
The latest filing identifies Contineum Therapeutics, Inc. by CUSIP 21217B100 and gives its principal executive office as 3565 General Atomics Court, Suite 200, San Diego, CA 92121 (SCHEDULE 13G/A, 2026-11-06).
What the percentages are based on
Each of the Reporting Persons may be deemed to be the beneficial owner of approximately 7.14% of the Shares, based on 32,723,877 Shares of Class A common stock outstanding as of April 30, 2026 as reported in the Issuer's 10-Q filed with the Securities and Exchange Commission on May 5, 2026.Balyasny Asset Management L.P., SCHEDULE 13G/A, 2026-08-14
The information requested in this item is incorporated herein by reference to the cover pages to this Schedule 13G/A. Percentage ownership is based on 35,353,313 shares of Class A Common Stock outstanding as of October 30, 2026, as reported in the Issuer's Report on Form 10-Q for the period ended September 30, 2026, as filed with the Securities and Exchange Commission on November 3, 2026.Johnson & Johnson Innovation - JJDC, Inc., SCHEDULE 13G/A, 2026-11-06
All such shares of Common Stock in the aggregate represent beneficial ownership of approximately 5.1% of the Common Stock based on (i) 32,958,632 shares of Common Stock outstanding, $0.001 par value per share, as of July 24, 2026, as reported by the Issuer on Form 10-Q filed with the Securities and Exchange Commission on July 30, 2026, plus (ii) 445,000 shares of Common Stock issuable upon exercise of the Options.Squadron Master Fund LP, SCHEDULE 13G, 2026-10-28
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-25 | RA Capital Management, L.P. | 9.9% | SCHEDULE 13G |
| 2025-08-05 | Franklin Resources, Inc. | 8.9% | SCHEDULE 13G/A |
| 2025-08-14 | Perceptive Advisors LLC | 3.2% | SCHEDULE 13G/A |
| 2025-11-04 | Franklin Resources, Inc. | 7.7% | SCHEDULE 13G/A |
| 2026-01-29 | Franklin Resources, Inc. | 6.2% | SCHEDULE 13G/A |
| 2026-02-17 | Balyasny Asset Management L.P. | 7.6% | SCHEDULE 13G |
| 2026-02-17 | Janus Henderson Group Plc | 7.9% | SCHEDULE 13G |
| 2026-02-17 | RA Capital Management, L.P. | 7.2% | SCHEDULE 13G/A |
| 2026-04-17 | Millennium Management LLC | 5.1% | SCHEDULE 13G |
| 2026-05-15 | Balyasny Asset Management L.P. | 7.4% | SCHEDULE 13G |
| 2026-05-15 | RA Capital Management, L.P. | 4% | SCHEDULE 13G/A |
| 2026-07-17 | Millennium Management LLC | 2.8% | SCHEDULE 13G/A |
| 2026-07-27 | BlackRock, Inc. | 6.3% | SCHEDULE 13G |
| 2026-08-14 | Balyasny Asset Management L.P. | 7.14% | SCHEDULE 13G/A |
| 2026-10-22 | Trails Edge Capital Partners, LP | 5.1% | SCHEDULE 13G |
| 2026-10-28 | Franklin Templeton, Inc. | 5.2% | SCHEDULE 13G/A |
| 2026-10-28 | Squadron Master Fund LP | 5.1% | SCHEDULE 13G |
| 2026-11-05 | Fmr LLC | 7.9% | SCHEDULE 13G |
| 2026-11-06 | Johnson & Johnson Innovation - JJDC, Inc. | 5.6% | SCHEDULE 13G/A |
Questions about who owns Contineum Therapeutics, Inc.
Who owns Contineum Therapeutics, Inc.?
On this page, 8 holders' latest ownership filings report 5% or more of Contineum Therapeutics, Inc.: Janus Henderson Group Plc (7.9%, Schedule 13G, filed 2026-02-17), Fmr LLC (7.9%, Schedule 13G, filed 2026-11-05), Balyasny Asset Management L.P. (7.14%, Schedule 13G/A, filed 2026-08-14), BlackRock, Inc. (6.3%, Schedule 13G, filed 2026-07-27) and Johnson & Johnson Innovation - JJDC, Inc. (5.6%, Schedule 13G/A, filed 2026-11-06); 3 more are listed above.
Who are the largest shareholders of Contineum Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Contineum Therapeutics, Inc. on this page are Janus Henderson Group Plc (7.9%), Fmr LLC (7.9%) and Balyasny Asset Management L.P. (7.14%).
When did Janus Henderson Group Plc buy into Contineum Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Janus Henderson Group Plc on this page is the Schedule 13G, filed 2026-02-17, reporting 7.9%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 19 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Contineum Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.